GBS Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GBS Inc. operates as a biosensor diagnostic technology company specializing in the development and commercialization of non-invasive diagnostic testing products. Its core products include the Saliva Glucose Biosensor, an organic thin-film biosensor designed to monitor glucose levels non-invasively through saliva, and a proprietary rapid drug screening system that analyzes fingerprint sweat to detect various substances. The company focuses on innovative biosensor platforms for diabetes monitoring and rapid drug screening tests. GBS targets healthcare providers and diagnostic markets primarily in the Asia-Pacific and North American regions. Founded in 1995, GBS Inc. is headquartered in Newport, Kentucky. In recent years, GBS has undergone significant strategic expansion, most notably through the acquisition of Intelligent Fingerprinting Limited (IFP), which added a rapid drug screening portfolio and an ISO 13485 certified manufacturing facility in the UK to its operations. This acquisition enhances GBS's leadership in non-invasive diagnostic testing beyond saliva-based products and aims to accelerate revenue growth by broadening its test offerings and customer base. GBS is advancing the commercialization of its saliva glucose biosensor and pursuing regulatory approvals to support sales growth via direct campaigns in new markets, including Australia. GBS's business segments include biosensor diagnostic technologies and rapid screening solutions with a strong focus on innovation and clinical validation. The company operates manufacturing and research facilities in the UK and Australia and maintains a presence in major healthcare markets globally, strategically positioning itself for growth in personalized medical diagnostics. This description captures GBS Inc.'s core products and services, recent major changes including the acquisition of Intelligent Fingerprinting Limited, geographic scope, and foundational details in a professional, formal tone suitable for financial data providers.
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
Is Intuit (INTU) Undervalued After Q3 FY26 Earnings? EPS $11.09 Beats Estimates, Revenue $8.56B Misses; GF Score 87/100, 51.2% Undervalued
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
Larry Robbins Increases Stake in DXC Technology Co
Kimberly-Clark Appoints Francesco Tinto as Chief Information & GBS Officer
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
GBS, Inc. (GBS) Q4 2022 Earnings Call Transcript
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
GBS Inc.'s (GBS) CEO Dr. Steven Boyages on Q3 2022 Results - Earnings Call Transcript
GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
4 Trending Penny Stocks to Add to Your Watchlist Right Now
GBS Inc. to Participate in the Upcoming March Investor Conferences